Biogen Idec/Elan Submit Tysabri sBLA For Crohn’s Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Submission includes labeling and risk management plan to address increased risk of progressive multifocal leukoencephalopathy.
You may also be interested in...
Joint Advisory Committee Will Grapple With Risk-Benefit Profile Of Tysabri For Crohn’s
Safety concerns, including the risk of PML, are still relevant considerations, briefing documents state.
Joint Advisory Committee Will Grapple With Risk-Benefit Profile Of Tysabri For Crohn’s
Safety concerns, including the risk of PML, are still relevant considerations, briefing documents state.
Tysabri Crohn’s sBLA Will Get Joint Advisory Committee Review
One of three progressive multifocal leukoencephalopathy deaths in Tysabri clinical database was in a Crohn’s patient.